Lyra Therapeutics stock holds its Nasdaq listing as results await

Published on 09/23/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lyra Therapeutics stock closed at a Nasdaq price dated September 22, 2026, while its latest reported period provides the operating baseline. The company remains a clinical-stage biotech.

LYRA, US55088T1025, Illustration mit AI erstellt.

Lyra Therapeutics stock (ISIN US55088T1025) remains a Nasdaq-listed clinical-stage biotechnology security, with the latest completed market session dated September 22, 2026. The company is developing medicines for diseases affecting the nose and upper airways, making clinical execution and financing central to the investment case.

Nasdaq status anchors the stock

MarketScreener identified the relevant Nasdaq session as closed at 10:00 p.m. on September 22, 2026, but the available market result did not provide a substantiated LYRA share price, daily percentage change, market capitalization, volume, or 52-week range. Those figures are therefore not stated as current market data.

The dated exchange context still matters because LYRA is a US issuer whose reference venue is Nasdaq and whose reference currency is USD. The September 22, 2026 session is the latest completed trading date visible in the available market context.

Clinical execution remains central

Lyra Therapeutics is a clinical-stage biotechnology company rather than a mature commercial pharmaceutical group. Its value therefore depends primarily on clinical progress, regulatory milestones, financing capacity, and the ability to translate research programs into approved products.

Reported revenue, earnings, margin, guidance, and other operating figures for the most recent eligible reporting period were not substantiated by the available dated results. No analyst rating, price target, contract announcement, acquisition, or explicitly dated upcoming reporting event is included here without a directly supporting source link.

Stock remains tied to evidence

For investors, the key distinction is between the company identity and the market catalyst. Lyra Therapeutics is consistently identified by ISIN US55088T1025, while the available September 2026 search results do not substantiate a specific LYRA event that can be presented as the day's catalyst.

The relevant monitoring points are concrete: a future clinical readout, a regulatory decision, financing terms, or a new report containing a dated revenue or earnings figure would materially improve the evidence base. Until then, the stock remains a biotechnology security whose financial profile must be assessed through the next substantiated company update.

Nasdaq reference remains September 22

Lyra Therapeutics stock is referenced to Nasdaq in USD, with the latest completed market-session date available being September 22, 2026. The company and ISIN remain the article's fixed identity reference.